ArticleNeurology2019
Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume.
Abstract read
In one paragraph
Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Microglial dynamics associate with the spatial pattern of tau deposition in early Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Metabolic Reprogramming of Brain Microglia: Implications for Aging and Aging-Associated Neurodegenerative Diseases.Aging cell · 2026Review
- Structural and molecular determinants of medial temporal lobe network vulnerability in aging and Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Dual association patterns between microglial activation and neuronal health in Alzheimer's disease: a whole-brain MRSI/PET study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Differential impact of manic versus depressive episode recurrence on longitudinal gray matter volume changes in bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Shannon Entropy of Gray Matter Eigenmodes: A Novel Biomarker for Alzheimer's Disease and Heterogeneous MCI Trajectories.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The effect of Apolipoprotein E4 on cognitive function in Parkinson's disease: A structural MRI study in the PPMI cohort.PloS one · 2026Article
- Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.Mathematical biosciences · 2025Article
- Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Single-nucleus transcriptomics reveals a distinct microglial state and increased MSR1-mediated phagocytosis as common features across dementia subtypes.Genome medicine · 2025Article
- Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.Molecular neurodegeneration · 2025Review
- Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates cognitive deficits in a mouse model of amyloidosis.Nature communications · 2025Article
- Neuroinflammation in Alzheimer disease.Nature reviews. Immunology · 2025Review
- Demyelination-derived lysophosphatidylserine promotes microglial dysfunction and neuropathology in a mouse model of Alzheimer's disease.Cellular & molecular immunology · 2025Article
- Microglial Modulation in Alzheimer's Disease: Central Players in Neuroinflammation and Pathogenesis.Current Alzheimer research · 2025Review
- The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.Brain communications · 2025Article
- Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study.Translational psychiatry · 2024Article
- Neural foundation of the diathesis-stress model: longitudinal gray matter volume changes in response to stressful life events in major depressive disorder and healthy controls.Molecular psychiatry · 2024Article
- Distinct spatial contributions of amyloid pathology and cerebral small vessel disease to hippocampal morphology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Grazia Daniela FemminellaFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Melanie DaniFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Melanie WoodFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Zhen FanFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Valeria CalsolaroFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Rebecca AtkinsonFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Trudi EdgintonFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Rainer HinzFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.ORCID 0000-0002-7808-9207
David J BrooksFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark.
Paul EdisonFrom the Department of Medicine (G.D.F., M.D., M.W., Z.F., V.C., R.A., D.J.B., P.E.), Imperial College London; Department of Psychology (T.E.), University of London, London; Wolfson Molecular Imaging Centre (R.H.), University of Manchester, UK; and Department of Nuclear Medicine (D.J.B.), Aarhus University, Denmark. paul.edison@imperial.ac.uk.
Funding
Medical Research Council G1100810Medical Research Council G84/6523Medical Research Council MC_U120036861
Abstract
objectiveTo investigate the influence of microglial activation in the early stages of Alzheimer's disease trajectory, we assessed the relationship between microglial activation and gray matter volume and hippocampal volume in patients with mild cognitive impairment (MCI).
methodsIn this study, 55 participants (37 with early stages of MCI and 18 controls) underwent [
resultsHigher [
conclusionsIn this in vivo study, we have demonstrated that microglial activation quantified using [
Indexed as
AgedAlzheimer DiseaseAmyloidCognitive DysfunctionFemaleGray MatterHippocampusHumansMagnetic Resonance ImagingMaleMicrogliaOrgan SizePilot ProjectsPositron-Emission TomographyAmyloid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.